has been cited by the following article(s):
|
[1]
|
Insulin Glargine in Critically ill Patients: Once/Day versus Twice/Day Dosing
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy,
2020
DOI:10.1002/phar.2373
|
|
|
|
|
[2]
|
Proportion and clinical profile of type 1 diabetes patients with a clinical time‐action of insulin glargine
U100
shorter than 24 hours
Practical Diabetes,
2020
DOI:10.1002/pdi.2274
|
|
|
|
|
[3]
|
Insulin Glargine in Critically ill Patients: Once/Day versus Twice/Day Dosing
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy,
2020
DOI:10.1002/phar.2373
|
|
|
|
|
[4]
|
Proportion and clinical profile of type 1 diabetes patients with a clinical time‐action of insulin glargine U100 shorter than 24 hours
Practical Diabetes,
2020
DOI:10.1002/pdi.2274
|
|
|
|
|
[5]
|
Twice-daily insulin glargine for patients with uncontrolled type 2 diabetes mellitus
Journal of Clinical & Translational Endocrinology,
2019
DOI:10.1016/j.jcte.2018.12.002
|
|
|
|
|
[6]
|
Insulin Glargine Dosing Every 16 Hours for a Complicated Type I Diabetes Case
AACE Clinical Case Reports,
2016
DOI:10.4158/EP151093.CR
|
|
|
|